SUNRISE, Fla., Jan. 17 /PRNewswire/ -- Bioheart, Inc., a biotechnology company focused on the development of innovative cell-based therapies for the treatment of heart attacks and congestive heart failure, announced today that Dr. Jorge Genovese has joined its Scientific Advisory Board. Dr. Genovese is a Research Professor in the Department of Surgery at the University of Pittsburgh Medical Center and he is a Research Associate of Cardiac Stem Cells Therapies of the McGowan Institute program. Dr. Genovese received his M.D. from the School of Medicine of Buenos Aires University, where he also obtained his Ph.D. after completing a thesis on TGF-Beta, an important growth factor involved in cell development and regeneration. He has been Vice-President of the Tissue Engineering Society International and is a member, among other institutions, of the Latin American Biomaterials and Artificial Organs Society and a founding member of the Latin American Association of Tissues Banks. He is Honorary President of the Tissue Engineering Committee at the National Academy of Science and Medicine of China. Dr. Genovese is a member of the editorial board of J. Stem Cells and the advisory board of Basic and Applied Myology.
Dr. Genovese has been devoted to different fields of tissue engineering including understanding how skeletal myoblasts might be used as a cell therapy for patients with heart disease. His research has also included testing the effects of electrical stimulation of myoblasts and adipose-derived stem cells prior to implantation. Now, Dr. Genovese’s research focuses on expanding this electrical stimulation work and on the basic aspects of adult stem-cells differentiation and cell therapies in cardiology.
“We are happy to welcome Dr. Genovese to our Scientific Advisory Board,” said Howard J. Leonhardt, Chairman and CEO of Bioheart. “We look forward to collaborating with Dr. Genovese in our efforts to develop novel cell therapies for patients with heart damage,” he added.
About Bioheart:
Bioheart, Inc. is a biotechnology company focused on the discovery, development and future commercialization of therapies using cells derived from a patient’s body, and related devices, for the treatment of heart damage. Our lead product candidate, MyoCell(R) implantation therapy, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with living muscle tissue for the purpose of improving cardiac function. Bioheart is currently testing MyoCell(R) and MyoCath(R), its proprietary catheter delivery system, for the non-acute treatment of damage to the heart in patients in Class II or Class III heart failure according to the New York Heart Association heart failure classification system. For more information about Bioheart, please visit http://www.bioheartinc.com or telephone Mr. Jason Griffeth at 954-835-1500.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management, may be deemed to be forward-looking statements. The words “targets,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions or negative variations thereof are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Investors and others are therefore cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our dependence on the success of our two lead product candidates, MyoCell(R) and MyoCath(R), (ii) the timely success and completion of our clinical trials, (iii) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates, (iv) our inability to predict the extent of our future losses or when or if we will become profitable, (v) our ability to secure additional financing to meet future capital requirements, (vi) our ability to protect our intellectual property rights and (vii) intense competition in the pharmaceutical, biopharmaceutical, medical device and biotechnology industries.
Bioheart, Inc.
CONTACT: Jason Griffeth of Bioheart, Inc., +1-954-835-1500
Web site: http://www.bioheartinc.com/
